Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (Atripla)

The Latest

This Week in HIV Research: HIV Is Not an Obstacle

April 11, 2019: acute syphilis and virologic control; neuropsychological performance after switching off efavirenz; structural LGBTQ stigma and HIV criminalization in U.S. states; lung cancer resection surgery in people with HIV.

By Barbara Jungwirth and Myles Helfand

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

By Sony Salzman

This Week in HIV Research: How Low (an Atripla Dose) Can You Go?

Atripla may be just as effective when taken every other day; poor antiretroviral prescription fill rates after hospitalization; U.S. progress against UNAIDS targets; hepatitis C transmission clustering in France.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: The Science of Risk

Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Check Your Frailty

The link between frailty and chronic disease development; Atripla’s long-term efficacy; the dangers of restrictive eligibility criteria for hepatitis C treatment; nicotine metabolism rates in people living with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Monday, Wednesday, Treatment Days

Happy days for thrice-weekly dosing; shortfalls in chronic opioid therapy monitoring; neurocognition, treatment initiation, and high CD4; the link between influenza virus shedding and CD4 count.

By Barbara Jungwirth and Myles Helfand

Atripla 3 Days a Week for 2 Years: Pilot Switch Study Reports Undetectable Viral Load With Better Bone, Kidneys and Sleep

A small pilot study that switched people with undetectable viral load to reduced dosing for the Atripla reported no viral load rebounds with follow-up results out to two years.

By Simon Collins for HIV i-Base

Fewer Renal or Bone Events With Atripla Than Stribild in Large Database

Renal adverse events and fractures proved rare among people taking tenofovir disoproxil fumarate (TDF) as part of a single-tablet regimen in a large U.S. database of insured patients.

By Mark Mascolini

Complera Non-Inferior to Atripla and Better Tolerated, Study Finds

The STaR study compared Complera to Atripla and found that Complera was not only non-inferior to Atripla, it performed better in terms of HIV symptoms and quality of life.

By Barbara Jungwirth

Racial Differences Seen in Comparison of Stribild and Atripla as First-Line Therapy

A new study finds that black people are less likely to keep their viral load down on Atripla -- and that more trouble with side effects may be the reason.

By Myles Helfand